135 related articles for article (PubMed ID: 33559805)
1. Pharmaceutical good manufacturing practice: Leuplin
Wada M; Ozaki A; Miyachi T; Tanimoto T; Crump A
Invest New Drugs; 2021 Aug; 39(4):1167-1169. PubMed ID: 33559805
[TBL] [Abstract][Full Text] [Related]
2. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
[TBL] [Abstract][Full Text] [Related]
3. [Accession to the PIC/S and pharmaceutical quality system in Japan].
Katori N
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):22-35. PubMed ID: 25707200
[TBL] [Abstract][Full Text] [Related]
4. Highlights of Good Manufacturing Practice in Japan.
Morita K
J Parenter Sci Technol; 1990; 44(1):35-8. PubMed ID: 2313491
[TBL] [Abstract][Full Text] [Related]
5. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
Tauqeer F; Myhr K; Gopinathan U
Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer].
Saito S; Nakashima J; Nakajima Y; Ikeuchi K; Shibayama T; Nagakura K; Naide Y; Hayakawa M; Ogawa Y; Hata M; Nakazono M; Hasegawa S; Oda T; Kimura S; Nakamura S; Matsunaga J; Fujioka T; Tanoguchi H; Aoki S; Yamamoto Y; Izawa A; Kimura S; Suzuki K; Tazaki H; Murai M;
Nihon Hinyokika Gakkai Zasshi; 2001 Nov; 92(7):682-93. PubMed ID: 11766367
[TBL] [Abstract][Full Text] [Related]
7. [Pharmaceutical product quality control and good manufacturing practices].
Hiyama Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
[TBL] [Abstract][Full Text] [Related]
8. Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.
Anyakora C; Ekwunife O; Alozie F; Esuga M; Ukwuru J; Onya S; Nwokike J
BMC Health Serv Res; 2017 Sep; 17(1):665. PubMed ID: 28923044
[TBL] [Abstract][Full Text] [Related]
9. Good manufacturing practice: the role of local manufacturers and competent authorities.
Tomić S; Filipović Sučić A; Ilić Martinac A
Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
[TBL] [Abstract][Full Text] [Related]
10. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
Geyer ARC; Sousa VD; Silveira D
PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical GMP: past, present, and future--a review.
Patel KT; Chotai NP
Pharmazie; 2008 Apr; 63(4):251-5. PubMed ID: 18468382
[TBL] [Abstract][Full Text] [Related]
12. Corporate Characteristics and Adoption of Good Manufacturing Practice for Dietary Supplements in Japan.
Sato K; Kodama K; Sengoku S
Int J Environ Res Public Health; 2020 Jul; 17(13):. PubMed ID: 32630326
[TBL] [Abstract][Full Text] [Related]
13. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
[TBL] [Abstract][Full Text] [Related]
14. [PICS: pharmaceutical inspection cooperation scheme].
Morénas J
Ann Pharm Fr; 2009 Jan; 67(1):16-9. PubMed ID: 19152846
[TBL] [Abstract][Full Text] [Related]
15. Leuprolide acetate: pharmaceutical use and delivery potentials.
Teutonico D; Montanari S; Ponchel G
Expert Opin Drug Deliv; 2012 Mar; 9(3):343-54. PubMed ID: 22335366
[TBL] [Abstract][Full Text] [Related]
16. Vendor qualification for pharmaceutical excipients--GMP requirements and approach.
Patel KT; Chotal NP
Pharmazie; 2010 Nov; 65(11):783-90. PubMed ID: 21155382
[TBL] [Abstract][Full Text] [Related]
17. [Shortages of Prescription Drugs Due to Compliance and Quality Issues in Japan].
Izutsu KI; Abe Y; Kurita M; Yoshida H
Yakugaku Zasshi; 2023 Feb; 143(2):139-152. PubMed ID: 36418079
[TBL] [Abstract][Full Text] [Related]
18. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
Kato M; Ishikawa H; Okuhara T; Kiuchi T
Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
[TBL] [Abstract][Full Text] [Related]
19. Campaign manufacturing of highly active or sensitizing drugs: a comparison between the GMPs of various Regulatory Agencies.
Petrelli F; Scuri S; Grappasonni I; Nguyen CTT; Cocchini A; Magrini E; Caraffa A
Clin Ter; 2020; 170(1):e66-e73. PubMed ID: 31850487
[TBL] [Abstract][Full Text] [Related]
20. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
